K. Chwalisz

No ORCID on file · 15 papers in corpus
other 2019
Human reproduction open ·doi:10.1093/hropen/hoz027

STUDY QUESTION: What is the safety and efficacy profile during long-term (12-24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associa…

2019
·doi:10.31038/igoj.2019241
2016
·doi:10.1016/j.fertnstert.2016.07.794
diagnostic-accuracy 2014
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114553064

Endometriosis affects up to 10% of women of reproductive age and 176 million women worldwide. The prevalence in women with infertility is between 30% and 50% but may be higher in women with pelvic pain, interstitial cystitis, or irritable b…

guideline 2013
Human Reproduction ·doi:10.1093/humrep/det050

STUDY QUESTION: Is there a global consensus on the management of endometriosis that considers the views of women with endometriosis? SUMMARY ANSWER: It was possible to produce an international consensus statement on the current management …

observational 2011
Journal of medical economics ·doi:10.3111/13696998.2010.549532

OBJECTIVE: This descriptive study assessed the rate and costs of surgical procedures among newly diagnosed endometriosis patients. METHODS: Utilizing the Medstat MarketScan database, commercially insured women aged 18-45 with endometriosis…

review 2000
Steroids ·doi:10.1016/s0039-128x(00)00194-x

Both progesterone receptor modulators (PRMs) as well as pure progesterone antagonists (PAs) have numerous proven and potential therapeutic applications in female health care. Mifepristone, a PRM with only marginal agonistic activity, togeth…

nonrandomized-trial 2000
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem.85.9.6769

Several reports indicate that vascular endothelial growth factor (VEGF) expression is increased in endometrial glands and stroma during the menstrual phase in the human endometrium. Here we report that VEGF receptor type 2 (KDR), normally e…

lab-animal 2000
Journal of medicinal chemistry ·doi:10.1021/jm001000c

Herein we describe the chemical synthesis and pharmacological characterization of a novel, highly potent progesterone receptor (PR) antagonist, ZK 230211. The introduction of a 17alpha-pentafluorethyl side chain in the D-ring of the steroid…

other 1996
Fertility and sterility ·doi:10.1016/s0015-0282(16)58140-0

OBJECTIVE: To compare the expression of endometrial P receptors (PR) levels with markers of endometrial receptivity during the window of implantation. DESIGN: Prospective, controlled study to examine endometrial PR and three cycle-specific…

lab-animal 1995
Human Reproduction ·doi:10.1093/oxfordjournals.humrep.a135900

The effects of the progesterone antagonists (antiprogestins) onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis were studied in intact female rats. Endometriosis was induced by transplanting homologous endometrium to…

lab-animal 1995
Steroids ·doi:10.1016/0039-128x(94)00043-c

Mifepristone (RU 486), used clinically for the termination of early pregnancy, and its acetyl and 13-retro (13 alpha) analogs show potent antiproliferative effects against estrogen-dependent human breast tumors and endometriosis. However, t…

lab-animal 1991
Endocrinology ·doi:10.1210/endo-129-1-312

There is evidence from previous studies that progesterone antagonists (antigestagens) modify estrogen responses at endometrial and myometrial levels without having affinity to the estrogen receptor (ER). The purpose of the present study was…

other 1981
Ginekologia polska
other 1980
Endokrynologia Polska